The Technical Analyst
FibroGen Inc [FGEN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
FibroGen Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-7.87% $1.170
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 115.56 mill |
| EPS: | -2.92 |
| P/E: | -0.400 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 98.77 mill |
| Avg Daily Volume: | 2.83 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.400 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.07x |
| Company: PE -0.400 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.876 - 1.444 ( +/- 24.48%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-22 | Wettig Thane | Sell | 782 | Common Stock |
| 2024-03-07 | Wettig Thane | Buy | 50 000 | Common Stock |
| 2024-03-06 | Graham Juan | Buy | 781 | Common Stock |
| 2024-03-06 | Graham Juan | Sell | 422 | Common Stock |
| 2024-03-06 | Graham Juan | Sell | 20 327 | Common Stock |
| INSIDER POWER |
|---|
| 84.23 |
| Last 100 transactions |
| Buy: 2 910 120 | Sell: 281 890 |
Forecast:
16:00 - $1.160
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.160
Forecast 2: 16:00 - $1.160
Forecast 3: 16:00 - $1.160
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.170 (-7.87% ) |
| Volume | 1.277 mill |
| Avg. Vol. | 2.83 mill |
| % of Avg. Vol | 45.14 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FGEN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $2.37 | N/A | Active |
|---|
FGEN
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-02 17:46:00 - Press Release
Fibrogen Announces Topline Results From Phase 1 Monotherapy Study Of Fg-3246 In Patients With Metastatic Castration-resistant Prostate Cancer
San francisco, april 02, 2024 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) today announced topline data from the fortis therapeutics-sponsored phase 1 study of fg-3246 (also known as for46), a potential first-in-class anti-cd46 antibody drug conjugate (adc) with an mmae-containing payload, in a dose-escalation and dose-expansion trial enrolling patients with metastatic castration-resistant prostate cancer (mcrpc) whose tumors have progressed on at least one androgen receptor-signaling inhibitor (arsi).
2024-03-26 07:00:00 - Press Release
Fibrogen To Present At 23rd Annual Needham Virtual Healthcare Conference
San francisco, march 26, 2024 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) today announced that thane wettig, chief executive officer, will participate in a corporate presentation at the 23rd annual needham virtual healthcare conference on tuesday, april 9, 2024, from 3:00-3:40 pm eastern time. company management will also participate in virtual one-on-one meetings with investors during the conference.
2024-03-11 07:00:00 - Press Release
Fibrogen Appoints Deyaa Adib, M.d. As Chief Medical Officer
San francisco, march 11, 2024 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) today announced the appointment of deyaa adib, m.d., an executive leader with almost three decades of oncology development experience, as senior vice president & chief medical officer to oversee all global clinical development activities. the appointment is effective march 11, 2024.
2024-02-26 16:06:00 - Press Release
Fibrogen Reports Fourth Quarter And Full Year 2023 Financial Results
• topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2q 2024 • additional data from phase 1 monotherapy study of fg-3246 in metastatic castration-resistant prostate cancer (mcrpc) expected in 1q 2024 • fibrogen regains rights to roxadustat from astrazeneca in the united states and other astrazeneca territories, except china and south korea • fy 2023 total net revenue of $147.8 million, an increase of 5% year over year • robust roxadustat volume growth of 41% in china in fy 2023 compared to fy 2022 • successful execution of cost reduction plan; $248.1 million in cash provides cash runway into 2026 san francisco, feb. 26, 2024 (globe newswire) -- fibrogen, inc...
2024-02-26 16:05:00 - Press Release
Fibrogen Regains All Rights To Roxadustat From Astrazeneca In The United States And Other Astrazeneca Territories, Except China And South Korea
The fibrogen – astrazeneca china agreement for roxadustat remains in place fibrogen to explore licensing opportunities for roxadustat san francisco, feb. 26, 2024 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) announced today that fibrogen and astrazeneca have agreed to terminate the u.s./row roxadustat collaboration agreement entered into on july 30, 2013, under which astrazeneca held development and commercialization rights in the united states and other territories outside of china not licensed to astellas pharma inc. pursuant to a termination and transition agreement entered into between the parties, astrazeneca is returning all u.s./row roxadustat rights to fibrogen (with the exception of south korea) and providing certain assistance during a transition period...
Latest News
2024-03-20 15:45:00 - InvestorPlace
3 Nightmare Nasdaq Stocks Not Worth Holding Another Day
Stocks are at the mercy of many factors, and often, prices are just a poor earnings report or a negative headline away from a significant drop. There are times when nobody has any way of preparing.
2024-02-26 16:18:45 - Reuters
FibroGen regains rights to anemia drug from AstraZeneca
FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca after the companies mutually agreed to terminate their collaboration agreement.
2024-02-20 07:00:00 - GlobeNewsWire
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2023 financial results on Monday, February 26 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
2023-11-06 20:30:18 - Seeking Alpha
FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript
2023-11-06 18:47:33 - Zacks Investment Research
FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for FibroGen (FGEN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
2023-10-23 07:00:00 - GlobeNewsWire
FibroGen to Report Third Quarter 2023 Financial Results
SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
2023-10-19 14:38:48 - InvestorPlace
7 Stocks to Sell Before the Axe Falls
While a contentious topic, investors seeking long-term success must frequently consider stocks to sell. Similar to changing the oil in a combustion-powered car, you've got to keep the overall machinery running well.
2023-08-30 12:46:56 - Zacks Investment Research
FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23%
FibroGen (FGEN) falls 22.7% as its late-stage study of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy fails to meet the primary endpoint.
2023-08-30 09:39:54 - Proactive Investors
FibroGen stock plummets as muscular dystrophy drug trial fails
FibroGen Inc (NASDAQ:FGEN) plummeted some 27% lower in Wednesday's early deals after revealing that its intended treatment for Duchenne muscular dystrophy failed to achieve primary and secondary endpoints in a clinical study. In the trial, the potential drug, pamrevlumab, had targeted an improvement in an ambulatory assessment score at 52 weeks in boys with DMD, ages six through 11.
2023-08-30 07:55:00 - Market Watch
FibroGen shares fall after failure in late-stage study of Duchenne muscular dystrophy treatment
Shares of FibroGen Inc. FGEN, +3.23% fell 23% premarket on Wednesday after the company said its investigational treatment for Duchenne muscular dystrophy failed to meet its primary and secondary endpoints in a clinical study. The treatment, pamrevlumab, did not achieve the targeted improvement in an ambulatory assessment score at 52 weeks in boys ages six through 11 with ambulatory Duchenne muscular dystrophy, FibroGen said in a release.